New drug hope for muscle weakness disease enters early human testing
NCT ID NCT07215650
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug called cizutamig in 44 adults with generalized myasthenia gravis, a condition causing muscle weakness. The main goal is to check safety and how the body processes the drug. Participants must have moderate symptoms and not have responded well to standard treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huashan Hospital Affiliated to Fudan University
RECRUITINGShanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at debilitating muscle weakness
- New hope for myasthenia gravis: experimental drug CNP-106 enters human trials
- New hope for myasthenia gravis patients: experimental drug enters phase 2 trial
- New drug trial aims to ease muscle weakness in rare disease
- New shot could ease daily struggles for myasthenia gravis patients
- New study lets myasthenia gravis patients rate their own symptoms on a new drug